Robeauté is pioneering a new class of therapeutic microrobots - engineered to diagnose, treat and monitor the brain with unprecedented flexibility and precision. At the convergence of robotics, physics, material science, chemistry, biology, and medicine, the company is building the future of neurosurgery. The microrobot is a modular medical device designed around a universal robotic core, equipped with interchangeable micro-extensions. This flexibility allows it to adapt to a wide range of clinical applications from sampling tissue to delivering targeted therapies, to implanting electrodes and collecting real-time data from deep within the brain.
Since its founding in 2017, Robeauté has established over 50 patents and unique knowledge from creating and assembling into the carrier an engine, propeller, steering and tracking device that enables surgeons to monitor the microrobot's movement through the brain. The company recently raised $28 million (€27M) in Series A funding led by Plural, Cherry Ventures, Kindred Ventures, and strategic investment from Brainlab. The technology is currently in animal studies as a biopsy tool, with human clinical trials targeted for 2026/2027. Backed by prestigious organizations including EIT Health, Bpifrance, and the European Innovation Council, Robeauté has been recognized with numerous awards including 1st place at MEDICA Start-up competition, WIRED Health Digital Health & Medical Devices, and Hello Tomorrow Global Challenge.